TXMD - Earnings announcements

- Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2022. "Our products continue to be adopted by healthcare providers and patients, and we continue to believe that they represent a significant opportunity. Our prescriber bases grew, and we added around 1,500 new prescribers for ANNOVERA and around 1,600 for IMVEXXY. Total quarterly prescriptions for both products remained relatively stable compared to the second

- Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. "We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA has significantly enhanced our ability to meet demand for the product.

-Executive Management to Host Conference Call on August 15, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date:   Monday, August 15, 2022 Time:   8:30 a.m. ET Audio Conference Line   https://register.vevent.com/register/BI7d111b66df2f4e8f849bb6048c1fa4d1 Webcast Link:  

- Quarterly total net product revenue of $19.3 million - - ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare divestiture in five weeks - - Conference call scheduled for 4:30 p.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the first quarter ended March 31, 2022. "Our revenue performance during the quarter was impacted by ANNOVERA manufacturing challenges as anticipated, but we believe these obstacles peaked in the first quarter of 2022 and expect incremental improvement as the year progresses. I'm also pleased to report that the $1

-Executive Management to Host Conference Call on May 16, 2022, at 4:30 p.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its first quarter 2022 financial results on Monday, May 16, 2022, after the closing of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date:   Monday, May 16, 2022 Time:   4:30 p.m. ET Telephone Access (US):   866-665-9531 Telephone Access (Intl):   724-987-6977 Conference ID:   3179996 Webcast:   https://edge.medi

- Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women's healthcare - - Amended credit terms with Sixth Street in support of a new capitalization plan - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the fourth quarter ended December 31, 2021. "We spent the past three months executing on four key priorities set forth last quarter, and today we announced that we have accomplished two of them. With the definitive agreement to fully divest our vitaCare busines

-Executive Management to Host Conference Call on March 10, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its fourth quarter 2021 financial results on Thursday, March 10, 2022, before the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Thursday, March 10, 2022 Time: 8:30 a.m. ET Telephone Access (US): 866-665-9531 Telephone Access (Int'l): 724-987-6977 Conference ID: 6988467 Webcast: https://ed

- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 - - ANNOVERA® TRx of 8,351, an increase of 62.7% over Q3 2020 - - Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savings of approximately $20 million annualized tied to the divestiture of vitaCare - - Hugh O'Dowd, President, to become Chief Executive Officer; Robert Finizio appointed Vice Chair of the Board - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2021. In addi

-Executive Management to Host Conference Call on November 11, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Thursday, November 11, 2021 Time: 8:30 a.m. ET Telephone Access (US): 866-665-9531 Telephone Access (International): 724-987-6977 Conference ID: 6341637 Webcast: h

- 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million - - ANNOVERA® prescription growth supported by improved access to providers and increased telemedicine options for patients - - Prescriptions for IMVEXXY® grew by 8% over 1Q21, outpacing the VVA market - - Centers for Medicare and Medicaid Services recommended that ANNOVERA receive its own unique national J-Code that could be live as early as Q421 - - vitaCare signed new customer and pipeline continues to grow - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for

-Executive Management to Host Conference Call on August 4, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET to discuss the Company's financial results and provide a business update. Conference Call & Audio Webcast Details Date Wednesday, August 4, 2021 Time 8:30 a.m. ET Telephone Access: U.S. and Canada 866-665-9531 Telephone Access: Internation